Glaukos and iVeena Delivery Systems have entered into a strategic licensing agreement that grants Glaukos an exclusive global license to develop and commercialize IVMED-80 for the treatment of keratoconus, according to a press release.
Glaukos paid iVeena $10 million upfront and will assume all costs associated with development and regulatory activities of IVMED-80, a topical eye drop with orphan drug designation that treats keratoconus by upregulating lysyl oxidase and inducing pharmacologic corneal cross-linking to strengthen the cornea.
The deal also includes potential development and sales